1-2 of 2
Keywords: Janus kinase
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Use of Ruxolitinib in Patients with Myelofibrosis and Anemia or Thrombocytopenia at Diagnosis

Open Access
Subject Area:
Hematology , Oncology
Jingbo Yu, Emily Bland, Tammy Schuler, Thomas Cordaro, Evan Braunstein
Journal: Acta Haematologica
Acta Haematol 408–418.
https://doi.org/10.1159/000541549
Published Online: 21 October 2024
... to in the content or advertisements. 2024 Myelofibrosis Anemia Thrombocytopenia Janus kinase Real-world Myelofibrosis (MF) is a progressive myeloproliferative neoplasm characterized by megakaryocyte proliferation, constitutional symptoms due to inflammatory cytokine production, bone marrow...
View article titled, Real-World Use of Ruxolitinib in Patients with Myelofibrosis and Anemia or Thrombocytopenia at Diagnosis
Open the PDF for Real-World Use of Ruxolitinib in Patients with Myelofibrosis and Anemia or Thrombocytopenia at Diagnosis in another window
Journal Articles

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes

Open Access
Subject Area:
High Impact Articles in Hematology , Hematology , Oncology
Aaron T. Gerds, Jingbo Yu, Robyn M. Scherber, Dilan Paranagama, Jonathan K. Kish, Jay Visaria, Mukul Singhal, Srdan Verstovsek, Naveen Pemmaraju
Journal: Acta Haematologica
Acta Haematol (2022) 145 (4): 448–453.
https://doi.org/10.1159/000520440
Published Online: 10 January 2022
..., methods, instructions or products referred to in the content or advertisements. [email protected] 28 06 2021 16 10 2021 10 1 2022 Janus kinase Myelofibrosis Re-treatment Ruxolitinib Ruxolitinib is a Janus kinase (JAK)1/JAK2 inhibitor approved by the US Food...
View article titled, Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Open the PDF for Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes in another window